Global Corporate Affairs Archives | Page 52 of 1087 | Be Korea-savvy

Archive by category Global Corporate Affairs

Vicor steps up its IP licensing practice

Vicor steps up its IP licensing practice

Licensing enables resilient, scalable supply chains in AI, automotive and industrial markets ANDOVER, Mass., Oct. 20, 2025 (Korea Bizwire) – Vicor Corporation (NASDAQ: VICR) Intellectual Property (IP) stemming from Vicor’s development of high-density power system technology is key to performance in high growth markets such as AI. Licensed access to foundational IP, including to 800V, [...]

A New Era for Research Impact: AACSB, AOM, and Global Partners Invite Public Feedback on Landmark Framework

A New Era for Research Impact: AACSB, AOM, and Global Partners Invite Public Feedback on Landmark Framework

TORONTO, Oct. 20, 2025 (Korea Bizwire) – AACSB International (AACSB) and Academy of Management (AOM) in collaboration with eight leading organizations from the business academic and scholarly community today released the Global Research Impact Framework: Exposure Draft, a major step toward expanding the reach, relevance, and rigor of business school research worldwide. The Global Research Impact Task Force, [...]

KFSHRC Performs World’s First Robotic Intracranial Tumor Resection … A New Era in Neurosurgery

KFSHRC Performs World’s First Robotic Intracranial Tumor Resection … A New Era in Neurosurgery

RIYADH, Saudi Arabia, Oct. 20, 2025 (Korea Bizwire) – In a historic leap for robotic medicine, King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world’s first robotic intracranial tumor resection, a groundbreaking achievement that sets a new global standard in neurosurgical precision and recovery. The surgery was conducted on [...]

Evergreen Line selects ORBCOMM’s smart dry container solutions

Evergreen Line selects ORBCOMM’s smart dry container solutions

Adoption of smart dry container technology at scale delivers flexibility, security, and richer cargo intelligence STERLING, Va., Oct. 20, 2025 (Korea Bizwire) – ORBCOMM® today announced that Evergreen Line is equipping its dry container fleet with ORBCOMM’s smart container technology. “This move signals a broader shift in the maritime industry where dry containers are rapidly [...]

SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System

SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System

FDA cleared and U.S. manufactured implant system positions SINTX to enter billion-dollar U.S. market SALT LAKE CITY, Utah, Oct. 20, 2025 (Korea Bizwire) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramics specializing in biomedical applications of silicon nitride (Si₃N₄), today announced U.S. Food and Drug Administration (FDA) 510(k) clearance [...]

Datavault AI (NASDAQ: DVLT) Partners with Max International AG to Launch Swiss Digital RWA Exchange, Overcoming Barriers to Institutional Tokenization

Datavault AI (NASDAQ: DVLT) Partners with Max International AG to Launch Swiss Digital RWA Exchange, Overcoming Barriers to Institutional Tokenization

Landmark Collaboration Harnesses Patented AI, Swiss Regulatory Fortress, and Fiduciary Expertise to Tokenize $1 Trillion1 + Global RWA Market, Anchored in Zurich’s Gold Hub BEAVERTON, Ore., Oct. 20, 2025 (Korea Bizwire) – via IBN — Datavault AI Inc. (NASDAQ: DVLT), a pioneer in patented AI-driven blockchain for secure data and asset monetization, today announces a [...]

Brothers, 19 and 20, Stanford dropouts, raise $4.1M in oversubscribed seed round to build Golpo AI and reimagine AI video generation

Brothers, 19 and 20, Stanford dropouts, raise $4.1M in oversubscribed seed round to build Golpo AI and reimagine AI video generation

Golpo AI secures oversubscribed seed round to transform communication through interactive AI videos SAN FRANCISCO, Oct. 20, 2025 (Korea Bizwire) – Golpo, the AI-powered platform that transforms documents and prompts into interactive explainer videos, announced today it has raised $4.1 million in a heavily oversubscribed seed round led by BNVT Capital (spin out from the [...]

StoneX Expands Wealth Management Offering for Latin American Clients

StoneX Expands Wealth Management Offering for Latin American Clients

NEW YORK, Oct. 17, 2025 (Korea Bizwire) – StoneX Group Inc. (NASDAQ: SNEX), a global financial services firm connecting clients to the markets across asset classes and geographies, today announced it has completed its acquisition of Intercam Advisors, Inc. and Intercam Securities, Inc., —U.S.-based firms providing brokerage and investment advisory services to Latin American clients. [...]

Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented for the first time at ESMO 2025.  Confirmed response by blinded independent central review was 77%, with 96% of patients achieving disease control.1  Zongertinib recently received Breakthrough Therapy Designations for first-line treatment by the [...]

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

SHANGHAI, Oct. 16, 2025 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the investigational new drug (“IND”) application for an open-label, two-arm, randomized, active-controlled, phase 2/3 clinical study comparing the company’s product, [...]